Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide

Autor: Parikh, Mamta, Tangen, Catherine, Hussain, Maha H.A., Gupta, Shilpa, Callis, Sam, Jo, Yeonjung, Harzstark, Andrea, Paller, Channing J., George, Saby, Zibelman, Matthew R., Cheng, Heather H., Maughan, Benjamin L., Zhang, Jingsong, Pachynski, Russell K., Bryce, Alan H., Lin, Daniel W., Quinn, David I., Lerner, Seth P., Thompson, Ian M., Dorff, Tanya B., Lara, Primo N., Agarwal, Neeraj
Zdroj: In European Urology Oncology October 2024 7(5):1097-1104
Databáze: ScienceDirect
Externí odkaz: